Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raily Aesthetic Medicine International Holdings (HKSE:02135) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Raily Aesthetic Medicine International Holdings ROCE % Related Terms
Raily Aesthetic Medicine International Holdings ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raily Aesthetic Medicine International Holdings ROCE % Chart
Raily Aesthetic Medicine International Holdings Annual Data
(1) Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Raily Aesthetic Medicine International Holdings (HKSE:02135) has a ROCE % of 17.43% as of Dec. 2025.
Is Raily Aesthetic Medicine International Holdings' ROCE % too high?
Raily Aesthetic Medicine International Holdings' current ROCE % is 17.43%. The Healthcare Providers & Services industry median ROCE % is 6.59. Raily Aesthetic Medicine International Holdings' value of 17.43% is 164.5% above this industry median. Overall, Raily Aesthetic Medicine International Holdings has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raily Aesthetic Medicine International Holdings' ROCE % compare to HCA and THC?
Raily Aesthetic Medicine International Holdings' ROCE % of 17.43% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.59. Raily Aesthetic Medicine International Holdings' value of 17.43% is 164.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.59, based on 643 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raily Aesthetic Medicine International Holdings's current ROCE % of 17.43% is 164.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raily Aesthetic Medicine International Holdings's current ROCE % is 17.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raily Aesthetic Medicine International Holdings stock overvalued right now?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings (HKSE:02135) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.14, compared to a current price of HK$0.12 — trading 15% below its estimated fair value. The current ROCE % is 17.43% and 164.5% above the Healthcare Providers & Services industry median of 6.59. Raily Aesthetic Medicine International Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Raily Aesthetic Medicine International Holdings (HKSE:02135), the current ROCE % is 17.43% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raily Aesthetic Medicine International Holdings (HKSE:02135) Overvalued in 2026?
Based on GuruFocus' analysis, Raily Aesthetic Medicine International Holdings stock appears to be undervalued.
The current stock price of HK$0.12 is trading 15% below its estimated GF Value™ of HK$0.14.
GuruFocus considers Raily Aesthetic Medicine International Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:02135:
ROCE %: 17.43%
GF Value™: HK$0.14 vs. price of HK$0.12 (15% below fair value)
Industry Position: 164.5% above the Healthcare Providers & Services median
No single metric tells the full story. See the HKSE:02135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raily Aesthetic Medicine International Holdings Ltd is an investment holding company. The company were principally engaged in the provision of aesthetic medical services, sale of aesthetic medical equipment products and provision of consulting services. The group is organized into three reportable operating segments namely Aesthetic medical services comprise principally inpatient services including surgical services and outpatient services including injection service, dermatology service and others; Aesthetic medical equipment products comprise principally sales of collagen injection products, surgical implants and aesthetic medical skincare products; Consulting services comprise principally management consulting services of which majority of revenue comes from Aesthetic medical services.
47GF Score
Get the complete analysis for HKSE:02135
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02135 has been successfully added to your 
